Combination treatment with bortezomib and thiostrepton is effective against tumor formation in mouse models of DEN/PB-induced liver carcinogenesis

Cell Cycle

Volumn 11, Issue 18, 2012, Pages 3370-3372

  Wang, Ming ^a   Halasi, Marianna ^a   Kabirov, Kasim ^a   Banerjee, Aryamitra ^a   Landolfi, Jennifer ^a   Lyubimov, Alexander V ^a   Gartel, Andrei L ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Bortezomib; Combination treatment; DEN PB; Liver cancer; Thiostrepton

Indexed keywords

BORTEZOMIB; DIETHYLNITROSAMINE; THIOSTREPTON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; LIVER CANCER; LIVER CARCINOGENESIS; MALE; MOUSE; NEWBORN; NONHUMAN; SHORT SURVEY;

EID: 84866744495     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.21290     Document Type: Short Survey

References (11)

1. Schoof S, Pradel G, Aminake MN, Ellinger B, Baumann S, Potowski M, et al. Antiplasmodial thiostrepton derivatives: proteasome inhibitors with a dual mode of action. Angew Chem Int Ed Engl 2010; 49:3317-21; PMID:20358566; http://dx.doi.org/10.1002/anie.200906988.
2. Bhat UG, Halasi M, Gartel AL. Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells. PLoS One 2009; 4:e5592; PMID:19440351; http://dx.doi.org/10.1371/journal.pone.0005592.
3. Pandit B, Gartel AL. Thiazole antibiotic thiostrepton synergize with bortezomib to induce apoptosis in cancer cells. PLoS ONE 2011; 6:e17110; PMID:21365012; http://dx.doi.org/10.1371/journal.pone.0017110.
4. Wang M, Gartel AL. Micelle-encapsulated thiostrepton as an effective nanomedicine for inhibiting tumor growth and for suppressing FOXM1 in human xenografts. Mol Cancer Ther 2011; 10:2287-97; PMID:21903609; http://dx.doi.org/10.1158/1535-7163.MCT-11-0536.
5. Wang M, Gartel AL. Combination with bortezomib enhances the antitumor effects of nanoparticle-encapsulated thiostrepton. Cancer Biol Ther 2012; 13:184-9; PMID:22353937; http://dx.doi.org/10.4161/cbt.13.3.18875.
6. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002; 8:2505-11; PMID:12171876.
7. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 22:2108-21; PMID:15169797; http://dx.doi.org/10.1200/JCO.2004.02.106.
8. Braet F, Wisse E. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol 2002; 1:1; PMID:12437787; http://dx.doi.org/10.1186/1476-5926-1-1.
9. Wisse E, Jacobs F, Topal B, Frederik P, De Geest B. The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Ther 2008; 15:1193-9; PMID:18401434; http://dx.doi.org/10.1038/gt.2008.60.
10. Crawford LJ, Walker B, Ovaa H, Chauhan D, Anderson KC, Morris TC, et al. Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res 2006; 66:6379-86; PMID:16778216; http://dx.doi.org/10.1158/0008-5472.CAN-06-0605.
11. Gusarova GA, Wang IC, Major ML, Kalinichenko VV, Ackerson T, Petrovic V, et al. A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment. J Clin Invest 2007; 117:99-111; PMID:17173139; http://dx.doi.org/10.1172/JCI27527.